About Cure IBM

Cure IBM is dedicated to inclusion body myositis awareness, education, and research.

Cure IBM is a California public benefit nonprofit organization, but does not accept donations. However, Cure IBM does strongly encourage donations to support IBM research. Please see the Donation page for recommendations.

Chairman

Kevin Dooley, MD

Dr. Dooley is the Chairman and author of Cure IBM. He has inclusion body myositis. He is a retired ophthalmologist, and is the former Chief of Ophthalmology at Kaiser South Sacramento Medical Center in California. He received his MD degree from Harvard Medical School.

Medical Advisors

Thomas E. Lloyd, MD, PhD

Dr. Lloyd is Professor and Chair of Neurology at Baylor College of Medicine (BCM) in Houston, Texas. He specializes in degenerative diseases of the neuromuscular system, such as inclusion body myositis (IBM) and amyotrophic lateral sclerosis (ALS). Dr. Lloyd received his medical degree and Ph.D. in molecular and cellular biology from BCM, and then completed his medicine internship, neurology residency, and post-doctoral fellowship in neuromuscular disorders at Johns Hopkins Hospital. After his training, he joined the faculty at Johns Hopkins, where he served as co-director of the Johns Hopkins Myositis Center. He is a leading researcher on inclusion body myositis, and has published numerous articles about IBM in high-profile journals. His laboratory studies IBM using mouse models as well as using patient-donated blood and muscle tissue samples. He has been site Principal Investigator for several prospective IBM clinical trials.

Conrad C. Weihl, MD, PhD

Dr. Weihl is Professor of Neurology at the Washington University School of Medicine in St. Louis, MO. He specializes in the treatment of patients with neuromuscular disorders within the Washington University Comprehensive Neuromuscular Clinic. He has a particular interest in disorders that cause muscle weakness and atrophy, such as inclusion body myositis. After receiving his PhD at the University of Chicago, and his MD degree from the University of Chicago Pritzker School of Medicine, he completed his residency in neurology at Barnes-Jewish Hospital at Washington University School of Medicine. The Weihl Lab studies protein degradation pathways and their relation to aging, muscle weakness, and neurodegeneration. His lab has generated several pre-clinical models for the study of IBM and has investigated the genetic etiologies of hereditary and sporadic IBM. Dr. Weihl has been a member of The Myositis Association medical advisory board, the Muscular Dystrophy Association scientific review committee, the Muscle Study Group planning committee, and the World Muscle Society.

Cure IBM Medical and Legal Disclaimer

The Cure IBM Content is provided for informational purposes only and is not intended as medical or legal advice, or as a substitute for the medical advice of a physician or the legal advice of an attorney.

The contents of the Cure IBM website and blogs are for informational purposes only, and are not a substitute for professional medical diagnosis, treatment, or advice. You should contact a medical professional before making any personal medical decisions. Cure IBM will not respond to requests for personal advice.

Cure IBM is not responsible for any errors, omissions, or inaccuracies in the information provided by this website. Even if a statement is accurate, it may not apply to you and your specific situation. Cure IBM is not responsible or liable for any damages suffered as a result of your reliance on the information contained in this site. Cure IBM does not endorse any treatments, tests, procedures, products, physicians, or opinions discussed on this website or blogs.

Links to third party websites from Cure IBM are not an endorsement of that site, its author(s), or its content, unless specifically stated otherwise. Your use of this website is conditioned upon your agreement to the contents of this disclaimer. If you do not agree with all parts of this medical disclaimer, you must immediately stop accessing our website.

Last Update of Medical and Legal Disclaimer: 8/29/2017

 

Financial Information

Tax-Exempt Status

Fiscal year 2021 990-PF

Fiscal year 2022 990-PF

Support IBM Research

Join Cure IBM in the fight against Inclusion Body Myositis. Your support will help fund research and the development of treatment options for this debilitating disease.

Share This